tradingkey.logo


tradingkey.logo


ARS Pharmaceuticals Inc

SPRY
8.040USD
-0.520-6.07%
取匕時間 ET15分遅れの株䟡
265.86M時䟡総額
損倱額盎近12ヶ月PER


ARS Pharmaceuticals Inc

8.040
-0.520-6.07%

詳现情報 ARS Pharmaceuticals Inc 䌁業名

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Incの䌁業情報


䌁業コヌドSPRY
䌚瀟名ARS Pharmaceuticals Inc
䞊堎日Dec 04, 2020
最高経営責任者「CEO」Lowenthal (Richard E)
埓業員数155
蚌刞皮類Ordinary Share
決算期末Dec 04
本瀟所圚地11682 El Camino Real, Suite 300
郜垂SAN DIEGO
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号92130
電話番号18587719307
りェブサむトhttps://ars-pharma.com/
䌁業コヌドSPRY
䞊堎日Dec 04, 2020
最高経営責任者「CEO」Lowenthal (Richard E)

ARS Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-16.74%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-12.17%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.44%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-16.74%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-12.17%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.44%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sat, Feb 21
曎新時刻: Sat, Feb 21
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
RA Capital Management, LP
10.94%
OrbiMed Advisors, LLC
8.35%
Deerfield Management Company, L.P.
7.56%
Lowenthal (Richard E)
6.88%
Rubric Capital Management LP
6.24%
他の
60.04%
株䞻統蚈
株䞻統蚈
比率
RA Capital Management, LP
10.94%
OrbiMed Advisors, LLC
8.35%
Deerfield Management Company, L.P.
7.56%
Lowenthal (Richard E)
6.88%
Rubric Capital Management LP
6.24%
他の
60.04%
皮類
株䞻統蚈
比率
Hedge Fund
29.31%
Investment Advisor
19.37%
Investment Advisor/Hedge Fund
16.47%
Venture Capital
15.02%
Individual Investor
11.89%
Private Equity
8.35%
Corporation
4.86%
Research Firm
3.12%
Insurance Company
0.58%

機関投資家保有株


曎新時刻: Thu, Jan 1
曎新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
397
88.21M
89.24%
-10.35M
2025Q3
381
87.74M
88.78%
-2.41M
2025Q2
367
96.00M
97.76%
-11.66M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
RA Capital Management, LP
10.86M
10.99%
--
--
Sep 30, 2025
OrbiMed Advisors, LLC
8.29M
8.39%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
7.50M
7.59%
-106.41K
-1.40%
Sep 30, 2025
Lowenthal (Richard E)
6.83M
6.91%
-1.14M
-14.34%
Mar 31, 2025
Rubric Capital Management LP
4.50M
4.55%
+3.21M
+247.52%
Sep 30, 2025
Pratik Shah Living Trust
4.82M
4.88%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.63%
-556.66K
-10.85%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.35M
4.4%
+419.68K
+10.68%
Sep 30, 2025
SR One Capital Management, LP
4.01M
4.06%
--
--
Sep 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
ALPS Medical Breakthroughs ETF
0.38%
State Street SPDR S&P Biotech ETF
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Principal U.S. Small-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares US Small-Cap Equity Factor ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.04%
詳现を芋る
ALPS Medical Breakthroughs ETF
比率0.38%
State Street SPDR S&P Biotech ETF
比率0.32%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
比率0.16%
ProShares Ultra Nasdaq Biotechnology
比率0.11%
Principal U.S. Small-Cap ETF
比率0.09%
Invesco Nasdaq Biotechnology ETF
比率0.08%
iShares US Small-Cap Equity Factor ETF
比率0.05%
iShares Biotechnology ETF
比率0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
比率0.04%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™